Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Among authors: nademanee a. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, et al. Nademanee A, et al. J Clin Oncol. 1994 Oct;12(10):2176-86. doi: 10.1200/JCO.1994.12.10.2176. J Clin Oncol. 1994. PMID: 7523609 Clinical Trial.
High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, et al. Nademanee A, et al. Blood. 1995 Mar 1;85(5):1381-90. Blood. 1995. PMID: 7858268 Free article.
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.
Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Parker P, Stein A, Smith E, Planás I, Kashyap A, Spielberger R, Fung H, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Blume KG, Niland J, Forman SJ. Nademanee A, et al. Blood. 1997 Nov 15;90(10):3844-52. Blood. 1997. PMID: 9354650 Free article. Clinical Trial.
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Stiff PJ, et al. Among authors: nademanee ap. J Clin Oncol. 1998 Jan;16(1):48-55. doi: 10.1200/JCO.1998.16.1.48. J Clin Oncol. 1998. PMID: 9440722 Clinical Trial.
Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.
Margolin KA, Van Besien K, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O'Donnell MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJ. Margolin KA, et al. Among authors: nademanee ap. Biol Blood Marrow Transplant. 1999;5(1):36-45. doi: 10.1053/bbmt.1999.v5.pm10232739. Biol Blood Marrow Transplant. 1999. PMID: 10232739 Free article. Clinical Trial.
High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.
Nademanee A, Molina A, Fung H, Stein A, Parker P, Planas I, O'Donnell MR, Snyder DS, Kashyap A, Spielberger R, Bhatia R, Krishnan A, Sniecinski I, Vora N, Slovak M, Dagis A, Niland JC, Forman SJ. Nademanee A, et al. Biol Blood Marrow Transplant. 1999;5(5):292-8. doi: 10.1016/s1083-8791(99)70004-2. Biol Blood Marrow Transplant. 1999. PMID: 10534059 Free article. Clinical Trial.
186 results